
Granules India Ltd. share price
NSE: GRANULES · Healthcare
₹798.95 -1.75%
Closing price data, updated 17 Nov 2026. 52-week range: -13.5% from high, +50.8% above low.
Price₹798.95
Market cap₹21,794 Cr
P/E30.5
P/B3.32
ROE13.5%
ROCE15.2%
Debt / equity0.30
Dividend yield0.00%
EPS₹26.16
Book value₹240.73
Operating margin16.9%
Dipscan score54 / 100
Share: WhatsAppX / TwitterTelegram
Granules India Ltd. shareholding pattern
As of Sep 2026: Promoters 37.39%, FIIs 20.25%, DIIs 15.33%, Government 0.00%, Public 17.94%, Others 9.10%.
| Holder | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|---|
| Promoters | 37.39% | 38.02% | 38.02% | 38.82% | 38.82% | 38.82% |
| FIIs | 20.25% | 17.50% | 15.31% | 13.55% | 14.09% | 13.24% |
| DIIs | 15.33% | 16.11% | 17.01% | 17.48% | 17.92% | 23.53% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 17.94% | 17.85% | 19.09% | 19.19% | 18.28% | 24.41% |
| Others | 9.10% | 10.53% | 10.58% | 10.96% | 10.89% | – |
| No. of Shareholders | 182,080 | 169,422 | 160,286 | 163,184 | 165,542 | 169,700 |
As filed by the company with the exchanges.
Returns
| 1 day | 1 week | 1 month | 3 months | 6 months | 1 year |
|---|---|---|---|---|---|
| -1.75% | -0.09% | -1.25% | -6.83% | +8.66% | +45.22% |
Growth
| Sales growth, 3 years | +5.9% |
| Sales growth, 5 years | – |
| Profit growth, 3 years | +4.8% |
| Profit growth, 5 years | – |
| Latest quarter sales vs last year | +18.8% |
| Latest quarter profit vs last year | +39.2% |
Strengths and weaknesses
Strengths
- Company has reduced debt.
Weaknesses
- Promoter holding has decreased over last quarter: -0.62%
- The company has delivered a poor sales growth of 10.6% over past five years.
- Company has a low return on equity of 13.7% over last 3 years.
- Dividend payout has been low at 7.84% of profits over last 3 years
Peers in Healthcare
| Company | Price | Market cap | P/E | ROE | 1 year |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | ₹1,867.50 | ₹4,48,076 Cr | 40.9 | 14.7% | +8.8% |
| Divi's Laboratories Ltd. | ₹11,080.00 | ₹2,94,139 Cr | 87.5 | 16.2% | +69.4% |
| Torrent Pharmaceuticals Ltd. | ₹4,691.20 | ₹1,78,438 Cr | 84.0 | 27.1% | +22.6% |
| Apollo Hospitals Enterprise Lt | ₹8,771.00 | ₹1,26,114 Cr | 56.2 | 21.9% | +16.9% |
| Laurus Labs Ltd. | ₹2,220.00 | ₹1,19,949 Cr | 89.5 | 18.2% | +125.2% |
| Zydus Lifesciences Ltd. | ₹1,192.00 | ₹1,18,902 Cr | 28.4 | 19.7% | +27.0% |
| Dr. Reddy's Laboratories Ltd. | ₹1,377.90 | ₹1,14,778 Cr | 41.0 | 12.1% | +13.7% |
| Cipla Ltd. | ₹1,394.50 | ₹1,12,658 Cr | 38.9 | 11.8% | -8.0% |
Frequently asked questions
What is the share price of Granules India Ltd.?
Granules India Ltd. (GRANULES) last closed at ₹798.95 (-1.75% on the day).
What is the market cap of Granules India Ltd.?
About ₹21,794 Cr.
What is the P/E ratio of Granules India Ltd.?
The price-to-earnings ratio is 30.5, and return on equity is 13.5%.
Figures are calculated from company results and exchange prices and are for information only.